8-K: Aimei Health Shareholders Approve United Hydrogen Merger

Aimei Health Technology Co., Ltd. shareholders approved the definitive business combination agreement with United Hydrogen Global Inc. and related proposals at an extraordinary general meeting.

Summary

• Aimei Health Technology Co., Ltd. (AFJK) held an Extraordinary General Meeting on November 6, 2025, where shareholders voted on key proposals related to its business combination with United Hydrogen Global Inc. (Pubco).
• The Business Combination Proposal and the Merger Proposal were both approved with 70.80% of votes cast in favor.
• The Share Issuance Proposal, authorizing the issuance of approximately 157,568,133 newly issued ordinary shares in the Business Combination, was approved with 67.23% of votes cast in favor.
• An Adjournment Proposal, allowing for the meeting to be adjourned if necessary for further proxy solicitation or to address redemption impacts on Nasdaq listing, was also approved with 67.23% of votes cast in favor.
• An aggregate of 3,950,411 Public Shares were tendered for redemption by holders of the company's outstanding ordinary shares.
• The company expects to complete the Business Combination as soon as practicable, subject to various conditions, including regulatory approvals.
• An Extension Proxy Statement was filed on November 10, 2025, for an extraordinary general meeting to approve an extension of the time to consummate the business combination, in case it cannot be completed before the current termination date of December 6, 2025.

Sentiment

Score: 4

Explanation: While the shareholder vote for the business combination was successful, the very high redemption rate (approximately 64.5%) and the need for an extension to complete the merger introduce significant uncertainty and potential capital constraints. This indicates a challenging path forward for the combined entity.

Positives

• Shareholders approved all key proposals related to the business combination, including the merger agreement, the merger itself, and the issuance of new shares, moving the transaction forward.
• The approval of the Adjournment Proposal provides the company with flexibility to address potential hurdles and ensure the business combination can be consummated.

Negatives

• A significant number of Public Shares (3,950,411) were tendered for redemption, which represents approximately 64.5% of the 6,121,733 outstanding ordinary shares on the record date, potentially impacting the capital available to the combined entity.
• The company has filed for an extension of the business combination completion deadline, indicating potential challenges or delays in closing the transaction by the original December 6, 2025 date.

Risks

• Uncertainties relating to the ability to complete the initial Business Combination.
• The possibility that the number of shares redeemed by public shareholders could prevent Pubco's ordinary shares from being approved for listing on a U.S. stock exchange.
• General risks and uncertainties indicated in filings with the U.S. Securities and Exchange Commission (SEC), including under the caption 'Risk Factors'.

Future Outlook

The company expects to use its best efforts to complete the Business Combination as soon as practicable, subject to various conditions, including regulatory approvals. An extraordinary general meeting is planned to approve an extension of the time to consummate the business combination, if necessary, beyond the current December 6, 2025 termination date.

Management Comments

• The Company expects to use its best efforts to complete the Business Combination as soon as practicable, subject to various conditions, including regulatory approvals.

Industry Context

This filing reflects a common trend in the SPAC (Special Purpose Acquisition Company) market, where a publicly traded shell company seeks to merge with a private operating company to take it public. The high redemption rate and the need for an extension vote are also common challenges faced by SPACs in the current market environment, indicating potential investor skepticism or market volatility.

Comparison to Industry Standards

• The approval percentages for the business combination proposals (around 70%) are generally sufficient for such transactions, though a higher 'for' vote would indicate stronger shareholder confidence.
• The redemption rate of approximately 64.5% (3,950,411 out of 6,121,733 outstanding shares) is very high compared to historical SPAC averages, which can severely deplete the trust account and make it challenging to meet minimum cash conditions for closing or Nasdaq listing requirements. Many SPACs in recent years have faced redemption rates exceeding 50%, often requiring additional financing or leading to deal cancellations.
• The need for an extension vote is a common occurrence for SPACs struggling to close deals within their initial timeframe, reflecting regulatory hurdles, market conditions, or difficulties in satisfying closing conditions, aligning with broader industry trends for SPACs in the current economic climate.

Stakeholder Impact

• Shareholders: Those who voted for the merger will receive shares of Pubco. Those who redeemed their shares will receive cash. The high redemption rate could dilute the value for remaining shareholders if the capital base is significantly reduced, and may impact the combined entity's ability to meet listing requirements.
• Employees: No direct impact mentioned, but the merger could lead to integration challenges or opportunities.
• Customers/Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Complete the Business Combination as soon as practicable, subject to regulatory approvals and other conditions.
• Hold the Extension EGM to approve an extension of the business combination completion deadline, if the Business Combination cannot be completed before December 6, 2025.
• Effect redemptions of tendered shares upon the closing of the Business Combination or upon the Extension EGM, depending on shareholder choices.

Key Dates

Recommendation

While the shareholder approval is a positive step towards completing the business combination, the very high redemption rate (approximately 64.5%) and the need for an extension to the merger deadline introduce significant uncertainty regarding the combined entity's capital structure and ability to meet listing requirements. Investors should hold to observe the outcome of the extension vote and the finalization of the business combination, as these factors will heavily influence the company's future valuation and operational capacity. The high redemptions suggest a cautious approach is warranted.

Keywords

Aimei Health Technology, AFJK, United Hydrogen Global, Business Combination, Merger, Shareholder Vote, SEC Filing, 8-K, Redemption, Nasdaq Listing, SPAC